Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 5% – Here’s Why

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s share price shot up 5% during mid-day trading on Wednesday . The company traded as high as $63.86 and last traded at $63.43. 297,710 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 1,253,954 shares. The stock had previously closed at $60.42.

Analyst Ratings Changes

A number of research firms recently commented on XENE. JPMorgan Chase & Co. raised their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Royal Bank Of Canada cut their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $77.13.

Xenon Pharmaceuticals Trading Up 5.1%

The firm’s 50-day moving average price is $62.65 and its 200 day moving average price is $56.05. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.40 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same period last year, the company posted ($1.07) earnings per share. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the transaction, the director directly owned 1,870 shares in the company, valued at $119,792.20. This represents a 84.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,512 shares of company stock valued at $774,088 in the last ninety days. 2.91% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 7.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after purchasing an additional 32,486 shares in the last quarter. Jump Financial LLC acquired a new position in Xenon Pharmaceuticals during the second quarter worth $532,000. Sei Investments Co. bought a new position in shares of Xenon Pharmaceuticals in the second quarter valued at $711,000. The Manufacturers Life Insurance Company bought a new position in shares of Xenon Pharmaceuticals in the second quarter valued at $816,000. Finally, Alliancebernstein L.P. grew its holdings in shares of Xenon Pharmaceuticals by 14.2% during the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after buying an additional 189,141 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.